Wockhardt Limited
WOCKPHARMA
Classifica tra le azioni
#4506
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Prezzo delle azioni
$21.02
Capitalizzazione di mercato
$3.42B
Variazione (1 giorno)
-2.48%
Variazione (1 anno)
37.78%
Paese
IN
Scambia Wockhardt Limited (WOCKPHARMA)
Categoria
Healthcare
EPS per Wockhardt Limited (WOCKPHARMA)
EPS al June 2026 TTM: $0.28
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Wockhardt Limited, l’EPS attuale della società (TTM) è $0.28. Alla fine del 2024, la società aveva un EPS di $-0.39 una diminuzione rispetto a rispetto a quello del 2023, che era di $-0.47.
Storico EPS per Wockhardt Limited da 2004 a 2026
EPS alla fine di ogni anno
| Anno | EPS | Cambia |
|---|---|---|
| 2026 (TTM) | $0.28 | -794.25% |
| 2025 | $-0.04 | -90.88% |
| 2024 | $-0.39 | -18.45% |
| 2023 | $-0.47 | 77.08% |
| 2022 | $-0.27 | -21.59% |
| 2021 | $-0.34 | 73.20% |
| 2020 | $-0.20 | -47.92% |
| 2019 | $-0.38 | -55.39% |
| 2018 | $-0.84 | 209.37% |
| 2017 | $-0.27 | -179.67% |
| 2016 | $0.34 | -41.89% |
| 2015 | $0.59 | -53.86% |
| 2014 | $1.28 | -51.83% |
| 2013 | $2.65 | 366.49% |
| 2012 | $0.57 | 232.75% |
| 2011 | $0.17 | -109.11% |
| 2010 | $-1.88 | 678.46% |
| 2008 | $-0.24 | -129.20% |
| 2007 | $0.83 | 80.04% |
| 2006 | $0.46 | -4.80% |
| 2005 | $0.48 | 16.08% |
| 2004 | $0.41 | 0.00% |
EPS per aziende simili o concorrenti
| Azienda | EPS | Differenza di EPS | Il paese |
|---|---|---|---|
| $2.41 | 767.84% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.52 | 87.25% |
US
|
